Filana Therapeutics, Inc. (FLNA) shareholders
Close on Nov 20, 2026Market cap $30.98MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FLNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,974,981 | 4.09% | $2.35M | +44,038 | 0.00% |
| Two Sigma Investments, LP | 1,711,358 | 3.54% | $2.04M | −277,456 | 0.00% |
| Marshall Wace, Llp | 1,597,548 | 3.31% | $1.90M | −414,995 | 0.00% |
| BlackRock, Inc. | 1,453,561 | 3.01% | $1.73M | +39,047 | 0.00% |
| Goldman Sachs Group Inc | 668,792 | 1.38% | $795.86K | +627,468 | 0.00% |
| Geode Capital Management, LLC | 615,510 | 1.27% | $732.74K | +19,268 | 0.00% |
| D. E. Shaw & Co., Inc. | 485,025 | 1.00% | $577.18K | −74,180 | 0.00% |
| Gmt Capital Corp | 450,100 | 0.93% | $535.62K | – | 0.03% |
| Renaissance Technologies LLC | 389,601 | 0.81% | $463.63K | +62,842 | 0.00% |
| Squarepoint Ops LLC | 318,380 | 0.66% | $378.87K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 315,889 | 0.65% | $375.91K | +41,958 | 0.00% |
| Acadian Asset Management LLC | 295,059 | 0.61% | $350.00K | +10,846 | 0.00% |
| Susquehanna International Group, Llp | 292,017 | 0.60% | $347.50K | −155,261 | 0.00% |
| Gsa Capital Partners Llp | 269,410 | 0.56% | $321.00K | +51,566 | 0.02% |
| Group One Trading, L.P. | 244,008 | 0.51% | $290.37K | −58,616 | 0.00% |
| State Street Corp | 209,105 | 0.43% | $248.84K | −30,882 | 0.00% |
| Vanguard Portfolio Management LLC | 132,597 | 0.27% | $157.79K | −96 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 132,298 | 0.27% | $157.44K | −4,633 | 0.00% |
| Federated Hermes, Inc. | 119,952 | 0.25% | $142.74K | +4,855 | 0.00% |
| Northern Trust Corp | 114,322 | 0.24% | $136.04K | −34,872 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 85 | 13M | 26.2% | 8 / 21 | 33 / 22 | 1M | 2M |
| Q1 2026 | 101 | 14M | 28.3% | 15 / 17 | 38 / 20 | 5M | 3M |
| Q4 2025 | 107 | 14M | 28.6% | 22 / 25 | 29 / 15 | 3M | 3M |
| Q3 2025 | 103 | 14M | 29.7% | 20 / 21 | 32 / 13 | 4M | 2M |
| Q2 2025 | 97 | 12M | 25.5% | 18 / 23 | 33 / 38 | 2M | 6M |
| Q1 2025 | 117 | 16M | 32.8% | 18 / 29 | 41 / 36 | 2M | 4M |
| Q4 2024 | 137 | 17M | 36.0% | 31 / 45 | 35 / 54 | 6M | 3M |
| Q3 2024 | 161 | 14M | 29.1% | 37 / 50 | 35 / 18 | 5M | 2M |
| Q2 2024 | 145 | 13M | 27.7% | 23 / 60 | 23 / 17 | 2M | 1M |
| Q1 2024 | 142 | 12M | 25.0% | 15 / 46 | 43 / 25 | 0M | 3M |
| Q4 2023 | 153 | 15M | 30.1% | 31 / 45 | 39 / 16 | 3M | 2M |
| Q3 2023 | 140 | 13M | 26.8% | 16 / 54 | 32 / 25 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
27 funds held FLNA in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FLNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,365,843 | 2.83% | $1.63M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 563,883 | 1.17% | $671.02K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 283,013 | 0.59% | $435.84K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 148,590 | 0.31% | $176.82K | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 132,117 | 0.27% | $203.46K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 81,461 | 0.17% | $125.45K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 72,474 | 0.15% | $111.61K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 42,605 | 0.09% | $50.70K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 39,953 | 0.08% | $61.53K | 0.00% | May 31, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 33,701 | 0.07% | $51.90K | 0.27% | May 31, 2026 |
| Fidelity ZERO Total Market Index Fund | 31,056 | 0.06% | $31.37K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 24,525 | 0.05% | $29.18K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 20,730 | 0.04% | $24.67K | 0.00% | Jun 30, 2026 |
| Fidelity ZERO Extended Market Index Fund | 16,078 | 0.03% | $16.24K | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 10,600 | 0.02% | $12.61K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard Barry | President & CEO, Director | 1,955,947 | 4.05% | Nov 20, 2026 |
| Eric Schoen | Chief Financial Officer | 31,500 | 0.07% | Nov 18, 2026 |
| Robert Christopher Cook | Chief Operating& Legal Officer | 135,300 | 0.28% | Nov 18, 2026 |
| Freda Nassif | Chief Business Officer | – | – | Apr 21, 2025 |
| James William Kupiec | Chief Medical Officer | 0 | – | Dec 3, 2024 |
| Robert Eugene Anderson Jr | Director | 27,600 | 0.06% | Nov 20, 2026 |
| Jill M. Quigley | Director | – | – | Nov 12, 2026 |
| Dawn Carter Bir | Director | – | – | Oct 22, 2025 |
| Patrick J. Md Scannon Phd | Director | 1,000 | 0.00% | Jul 16, 2025 |
| Pierre Gravier | Director | – | – | May 27, 2025 |
| Robert Z. Gussin | Director | 10,617 | 0.02% | May 27, 2025 |
| Claude Nicaise | Director | – | – | May 27, 2025 |
| Donnell Michael J. O | Director | 65,812 | 0.14% | May 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Eugene Anderson Jr Director | Nov 18, 2026 | Buy | +19,000 | $0.52 | $9.88K | 27,600 |
| Richard Barry President & CEO, Director | Nov 18, 2026 | Buy | +44,851 | $0.52 | $23.32K | 1,955,947 |
| Richard Barry President & CEO, Director | Nov 17, 2026 | Buy | +132,926 | $0.48 | $63.80K | 1,911,096 |
| Richard Barry President & CEO, Director | Nov 16, 2026 | Buy | +440,206 | $0.47 | $206.90K | 1,778,170 |
| Eric Schoen Chief Financial Officer | Nov 16, 2026 | Buy | +20,000 | $0.42 | $8.40K | 31,500 |
| Robert Christopher Cook Chief Operating& Legal Officer | Nov 16, 2026 | Buy | +121,575 | $0.46 | $55.92K | 135,300 |
| Richard Barry President & CEO, Director | Sep 30, 2026 | Buy | +100,000 | $0.92 | $92.00K | 1,337,964 |
| Richard Barry President & CEO, Director | Sep 29, 2026 | Buy | +206,813 | $0.90 | $186.13K | 1,237,964 |
| Richard Barry President & CEO, Director | Sep 28, 2026 | Buy | +93,091 | $0.84 | $78.20K | 1,031,151 |
| Robert Eugene Anderson Jr Director | Nov 24, 2025 | Buy | +8,600 | $2.90 | $24.94K | 8,600 |
| Richard Barry President & CEO, Director | Nov 20, 2025 | Buy | +150,000 | $2.76 | $414.00K | 938,060 |
| Richard Barry President & CEO, Director | Nov 19, 2025 | Buy | +73,385 | $2.75 | $201.81K | 788,060 |
| Robert Christopher Cook Chief Operating & Legal Office | Sep 30, 2025 | Buy | +13,725 | $2.91 | $39.94K | 13,725 |
| Richard Barry President & CEO, Director | Sep 22, 2025 | Buy | +7,172 | $2.28 | $16.35K | 714,675 |
| Richard Barry President & CEO, Director | Sep 19, 2025 | Buy | +46,908 | $2.29 | $107.42K | 707,503 |
| Richard Barry President & CEO, Director | Sep 19, 2025 | Buy | +400 | $2.25 | $900 | 660,595 |
| Richard Barry President & CEO, Director | Sep 18, 2025 | Buy | +185,233 | $2.24 | $414.92K | 660,195 |
| Richard Barry President & CEO, Director | Sep 18, 2025 | Buy | +5,400 | $2.13 | $11.50K | 474,962 |
| Eric Schoen Chief Financial Officer | Nov 29, 2024 | Sale | −59,800 | $3.86 | $230.83K | 11,500 |
| Eric Schoen Chief Financial Officer | Nov 29, 2024 | Sale | −2,000 | $3.82 | $7.64K | 0 |
| Eric Schoen Chief Financial Officer | Nov 29, 2024 | Option exercise | +50,000 | $1.18 | $59.00K | 71,300 |
| James William Kupiec Chief Medical Officer | Nov 29, 2024 | Sale | −4,000 | $3.87 | $15.48K | 0 |
| Sanford Robertson Director | May 16, 2024 | Gift | −5,000 | – | – | 950,851 |
| Sanford Robertson Director | May 16, 2024 | Gift | +5,000 | – | – | 5,000 |
| Sanford Robertson Director | Apr 26, 2024 | Option exercise | +69,000 | $22.00 | $1.52M | 955,851 |
| Richard Barry Director | Apr 23, 2024 | Option exercise | +176,085 | $22.00 | $3.87M | 469,562 |
| James William Kupiec Chief Medical Officer | Apr 18, 2024 | Option exercise | +1,500 | $22.00 | $33.00K | 4,000 |
| Eric Schoen Chief Financial Officer | Apr 17, 2024 | Option exercise | +1,500 | $22.00 | $33.00K | 21,300 |
| Sanford Robertson Director | Aug 23, 2023 | Buy | +30,000 | $17.45 | $523.50K | 886,851 |
| Richard Barry Director | Aug 22, 2023 | Buy | +16,571 | $16.65 | $275.91K | 293,477 |
| Richard Barry Director | Aug 21, 2023 | Buy | +1,906 | $16.80 | $32.02K | 276,906 |
| Patrick J. Md Scannon Phd Director | Jun 12, 2023 | Option exercise | +1,000 | $0.95 | $950 | 1,000 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Option exercise | +14,285 | $16.87 | $240.99K | 390,397 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Tax withholding | −47,723 | $25.25 | $1.21M | 734,279 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Option exercise | +71,428 | $16.87 | $1.20M | 782,002 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Tax withholding | −9,545 | $25.25 | $241.01K | 380,852 |
| Sanford Robertson Director | May 10, 2023 | Option exercise | +2,142 | $16.66 | $35.69K | 856,851 |
| Sanford Robertson Director | May 10, 2023 | Option exercise | +3,571 | $19.60 | $69.99K | 851,138 |
| Sanford Robertson Director | May 10, 2023 | Option exercise | +3,571 | $16.66 | $59.49K | 854,709 |
| Robert Z. Gussin Director | May 1, 2023 | Tax withholding | +7,077 | $23.34 | $165.18K | 10,617 |
| Robert Z. Gussin Director | May 1, 2023 | Option exercise | +2,142 | $16.66 | $35.69K | 10,552 |
| Robert Z. Gussin Director | May 1, 2023 | Option exercise | +3,571 | $16.66 | $59.49K | 14,123 |
| Robert Z. Gussin Director | May 1, 2023 | Option exercise | +3,571 | $19.60 | $69.99K | 17,694 |
| Donnell Michael J. O Director | Mar 7, 2023 | Tax withholding | −2,778 | $25.20 | $70.01K | 6,873 |
| Donnell Michael J. O Director | Mar 7, 2023 | Tax withholding | −2,361 | $25.20 | $59.50K | 9,651 |
| Donnell Michael J. O Director | Mar 7, 2023 | Option exercise | +3,571 | $19.60 | $69.99K | 12,012 |
| Donnell Michael J. O Director | Mar 7, 2023 | Option exercise | +3,571 | $16.66 | $59.49K | 8,441 |
| Richard Barry Director | Mar 7, 2023 | Buy | +77,276 | $25.76 | $1.99M | 275,000 |
| Richard Barry Director | Mar 6, 2023 | Buy | +11,565 | $26.13 | $302.19K | 197,724 |
| Nadav Friedmann Chief Medical Officer, Director | Oct 3, 2022 | Option exercise | +9,376 | $0.95 | $8.91K | 79,910 |
| Sanford Robertson Director | Sep 8, 2022 | Option exercise | +2,802 | $23.59 | $66.10K | 1,027,567 |
| Richard Barry Director | Aug 23, 2022 | Buy | +36,159 | $23.79 | $860.22K | 186,159 |
| James William Kupiec Chief Clinical Dev. Officer | Aug 23, 2022 | Buy | +2,500 | $24.44 | $61.10K | 2,500 |
| Eric Schoen Chief Financial Officer | Aug 12, 2022 | Buy | +2,500 | $19.95 | $49.88K | 19,800 |
| Sanford Robertson Director | Aug 12, 2022 | Buy | +100,000 | $20.69 | $2.07M | 1,024,765 |
| Remi Barbier President and CEO, Director | Jun 7, 2022 | Other | −57,143 | – | – | 710,574 |
| Remi Barbier President and CEO, Director | Jun 6, 2022 | Tax withholding | −54,720 | $27.93 | $1.53M | 767,717 |
| Remi Barbier President and CEO, Director | Jun 6, 2022 | Option exercise | +65,368 | $23.38 | $1.53M | 822,437 |
| Nadav Friedmann Chief Medical Officer, Director | May 27, 2022 | Tax withholding | −21,498 | $26.66 | $573.14K | 70,534 |
| Nadav Friedmann Chief Medical Officer, Director | May 27, 2022 | Option exercise | +3,501 | $23.38 | $81.85K | 70,590 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 9 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Filana Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 50,134 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Eric Schoen Officer | Dec 2, 2024 | 2,000 | $7.64K | Nov 29, 2024 | RETAIL PURCHASE |
| Eric Schoen Officer | Nov 29, 2024 | 59,800 | $230.97K | Nov 29, 2024 | STOCK OPTION EXERCISE |
Congress trades
5 trades in Filana Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Bought | Dec 12, 2022 | $1K–15K | Jan 20, 2023 |
| Christopher L. Jacobs NY27 | Sold | Nov 8, 2022 | $1K–15K | Dec 12, 2022 |
| Christopher L. Jacobs NY27 | Bought | Oct 12, 2022 | $1K–15K | Nov 16, 2022 |
| Christopher L. Jacobs NY27 | Sold | Jul 18, 2022 | $1K–15K | Sep 9, 2022 53 days late |
| Christopher L. Jacobs NY27 | Bought | Jun 21, 2022 | $15K–50K | Jul 28, 2022 |
See a number that looks wrong?